Positivity of the proliferation marker Ki-67 in noncycling cells

American Journal of Clinical Pathology

Volumn 110, Issue 1, 1998, Pages 24-31

  Van Oijen, Monique G C T ^a   Medema, René H ^a   Slootweg, Pieter J ^a   Rijksen, Gert ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cell cycle arrest; Immunohistochemistry; Ki 67; MIB 1; p21(Waf1 Cip1); p53; Proliferation

Indexed keywords

KI 67 ANTIGEN; PROTEIN P21; PROTEIN P53;

ARTICLE; CELL CYCLE G0 PHASE; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GROWTH RATE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

EID: 0031748305     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/110.1.24     Document Type: Article

References (30)

1. Gerdes J, Schwab U, Lemte H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13-20.
2. Ross W, Hall PA. Ki67: from antibody to molecule to understanding. J Clin Pathol Mol Pathol. 1995;48: M113-M117.
3. Duchrow M, Gerdes J, Schlüter C. The proliferation-associated Ki-67 protein: definition in molecular terms. Cell Prolif. 1994;27:235-242.
4. Loke SL, Jaffe ES, Neckers LM. Inhibition of in vitro DNA synthesis in human cells. Blood. 1987;70(suppl 1):157a. Abstract.
5. Wong FW. Immunohistochemical detection of proliferating tumor cells in cervical cancer using monoclonal antibody Ki-67. Gynecol Obstet Invest. 1994;37:123-126.
6. Chowdhury GM, Kojima K, Kanayama H, et al. The proliferation index of MIB-1 as a prognostic factor for patients with transitional cell carcinoma of the upper urinary tract. Cancer. 1996;78:827-833.
7. Muller W, Schneiders A, Meier S, et al. Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma. Br J Cancer. 1996;74:759-765.
8. Rudolph P, Lappe T, Hero B, et al. Prognostic significance of the proliferative activity in neuroblastoma. Am J Pathol. 1997;150:133-145.
9. Sasaki K, Matsumura K, Tsuji T, et al. Relationship between labeling indices of Ki-67 and BrdUrd in human malignant tumors. Cancer. 1988;62:989-993.
10. Goldblum JR, Appelman HD. Stromal tumors of the duodenum: a histologic and immunohistochemical study of 20 cases. Am J Surg Pathol. 1995;19:71-80.
11. Oka K, Arai T. MIB1 growth fraction is not related to prognosis in cervical squamous cell carcinoma treated with radiotherapy, Int J Gynecol Pathol. 1996;15:23-27.
12. van Dierendonck JH, Keijzer R, van de Velde CJH, et al. Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer Res. 1989;49:2999-3006.
13. Littleton RJ, Baker GM, Soomro IN, et al. Kinetic aspects of Ki-67 antigen in a normal cell line. Virchows Arch B Cell Pathol. 1991;60:15-19.
14. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133: 1710-1715.
15. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 1996;88:1442-1455.
16. Gartel AL, Serfas MS, Tyner AL. p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med. 1996;213:138-149.
17. waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene. 1998;16:431-441.
18. WAFI immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB-1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer. 1996;74:208-215.
19. Maestro R, Gloghini A, Doglioni C, et al. Human non-Hodgkin's lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent kinase inhibitor p21. Blood. 1997;89:2523-2528.
20. Slootweg PJ, Koole R, Hordijk GJ. The presence of p53 protein in relation to Ki-67 as cellular proliferation marker in head and neck squamous cell carcinoma and adjacent dysplastic mucosa. Eur J Cancer B Oral Oncol. 1994;30B: 138-141.
21. Wedenberg C, Johnsson A, Hirsch JM. Assessment of p53 and Ki-67 expression in snuff-induced lesions. Br J Cancer. 1996;34:409-413.
22. Diller L, Kassel J, Nelson CE, et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol. 1990;10:5772-5781.
23. Bruno S, Darzynkiewicz Z. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif. 1992;25:31-40.
24. Brock WA, Swartzendruber DE, Grdina DJ. Kinetic heterogeneity in density-separated murine fibrosarcoma subpopulations. Cancer Res. 1982;42:4999-5003.
25. 2 phase. Cell Tissue Kinet. 1984;17:453-463.
26. Copete MA, Wendt K, Chen SY. Expression of p53, Ki-67 and cytokeratin-4 (CK4) in oral papillomas. J Oral Pathol Med. 1997;26:211-216.
27. Ingle R, Setzen G, Koltai P, et al. p53 protein expression in benign lesions of the upper respiratory tract. Arch Otolaryngol Head Neck Surg. 1997;123:297-300.
28. cip1/waf1 protein accumulation in head-and-neck cancer. Int J Cancer. 1997;74:383-389.
29. Doglioni C, Pelosio P, Laurino L, et al. p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol. 1996;179:248-253.
30. Yasui W, Akama Y, Kuniyasu M, et al. Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol. 1996;180:122-128.